Overview of ACC`s National Cardiovascular Data Registry
Transcription
Overview of ACC`s National Cardiovascular Data Registry
National Quality Registry Network Webinar Series #1 Kathleen Hewitt, MSN, RN, AACC, CPHQ AVP, American College of Cardiology ©American College of Cardiology - EHRs; meaningful use - Public Reporting - Value based purchasing - Payment cuts - Accountable Care - Claims data profiling Organizations - Physician Quality Reporting System (PQRS) - Episode - Preauthorization - Payer Programs groupers - Efficiency metrics (= cut costs) - Hospital employment - Bundled payments (capitation) - Coverage determinations - Utilization review - MOC / MOL - Appropriateness auditing - Certification exams There’s a shift . . . : C MS ICD y istr g e R TVT y istr g e R An Emerging Vision of Registries at the ACC Gap Analysis Peerreviewed Research & Guidelines Registry Data Quality & Performance Improvement Why we invest Awareness 9Unique clinical information 9Enable performance measurement by physicians for physicians and hospitals 9Support for novel scientific research production 9Scaled delivery of registry‐ driven quality improvement programs 4 Can clinical registries help? Clinical Data Bufalino VJ et al. Circulation. 2011;123:2167-2179 2500 hospitals > 2000 cardiologists 20 million clinical records PVI 1998 2004 2005 2006 2007 2008 2010 2012 Participants, Patient Records, Manuscripts & Abstracts Name CathPCI (Diag. Cath &PCI) ICD ACTION Registry‐GWTG (STEMI & NSTEMI) CARE (CAS & CEA) IMPACT (Adult & Ped Congenital Intervention) PINNACLE (All CV Outpatient) STS/ACC TVT (Transcatheter Valve Therapy) # of Participants # of Patient Records 1500 14.5 million 1600 900,000 800 465,000 180 15,000 70 2000 2000 6.7 million 165 1500 NCDR Governance NCDR collaborations Maintenance Of Certification Open-book modules testing clinical and practical knowledge in a particular field. NCDR 3rd Party Reporting Services ent Cons ure signat How Registry Participation Works One master contract with addendums for each registry (except TVT) Many vendor options and NCDR offers complimentary web entry if needed Data Dictionary Alignment Vendors creating systems to avoid redundant data collection • New definition and technical alignment • Launch late 2013 Data Quality Program… • Training and Clinical Support Team – – – – – – Orientation webinars Online FAQs Live customer support Email Monthly webinars Annual meeting with case reviews, etc. • Data Entry Integrity – – – Value checks Range checks Parent:Child fields • Data Quality Report – – registry-specific algorithms predetermined levels of completeness and consistency required for data to be included in national and comparison group averages • Data Audit Program ¾ 300 to 625 records are audited annually, within 25 randomly identified sites. In the 2010 audits, the overall accuracy of data abstraction for the CathPCI, ICD, and ACTIONGWTG registries were, respectively, 93.1%, 91.2%, and 90.0%. JACC June, 2012 Annual NCDR Conference ACC.13 NCDR Session Series NCDR Dashboard • • • • • Executive summary metrics Performance measures Trending graphs Drill down to the patient level Unique comparison group filters Clinical data Quality benchmarks E-Report Executive Summary Detailed Graphs 1. Proportion of patients that receive an ICD that meet class I guideline indications. Comparison Groups 1. Participant 5. Comparison Group or Volume Group 2. Reporting Timeframe 6. State\Province 3. Metric Prompt 7. No Of Certified Beds 4. Teaching Institution New! Physician Level Dashboard • Hospital Exec Summary metrics reported at physician level • Used for a) b) c) d) Awareness Motivation Self directed PIM Education with CME, MOC and possibly MOL Volume Summary Different Perspectives Public reporting…. STS and Consumers Union Perspective: NEJM Oct 21, 2010 • ACC + SCAI + HRS + reporting partner • Hospital level measures • Voluntary reporting 2011 ACC Board motion 2012 2013-2014 Clinical registries provide a platform for phase 3 & 4 research Pre-Market Post-Market Role for New Generation of Clinical Registries Phase 4 Phase 1 • Safety is primary endpoint • Highly selected population (must meet several selection criteria) • Short duration Phase 2 • Safety and efficacy are primary endpoints • Highly selected population • Short duration Phase 3 • Safety and efficacy are primary endpoints • Selected population • Pivotal studies (randomized controlled trial, RCT) • Longer duration PostApproval • FDA driven and negotiated • Centers defined • Generally a Phase 3 continuance • Sample size pre-determined • Study interval defined PostMarket • Sponsor driven • Generally RCT or Claims based • Direct product comparisons • Costs collected • Sample size pre-determined • Study interval defined Traditional Registries • Product performance and safety data • Effectiveness is the primary endpoint • Hypothesis generating • Large and usually undefined sample size • Real world population • Continuous duration • Treatment not assigned Questions?
Similar documents
An Introduction to NCDR: Myths and Realities
systems to avoid redundant data collection
More information